Table 4:

Predictors for abnormal liver tests at time of hospital admission in patients with COVID-19

Characteristic	AST	ALT	ALP	TBIL	Albumin
Age, mean, years	64.3 vs. 66.0 (NS)	59.5 vs. 68.6 (<0.001)	62.8 vs. 65.2 (NS)	67.1 vs. 65.0 (NS)	61.9 vs. 67.2 (<0.001)
Male gender, n (%)	58.5 vs. 44.6% (<0.001)	64.7 vs. 46.2% (<0.001)	51.1 vs. 54.3% (NS)	75.7 vs. 53.2% (<0.001)	50.7 vs. 59.5% (0.016)
BMI (mean)	30.0 vs. 29.3 (NS)	30.8 vs. 29.1 (<0.001)	28.4 vs. 30.0 (0.002)	27.9 vs. 29.8 (0.037)	30.3 vs. 29.4 (0.012)
Diabetes mellitus (%)	38.4 vs. 41.8% (NS)	33.1 vs. 44.2% (<0.001)	40.1 vs. 39.5% (NS)	32.4 vs. 39.8% (NS)	40.1 vs. 39.1% (NS)
Preadmission AST Abnormal (%)	23.1 vs. 11.9% (<0.001)	32.9 vs. 13.4% (<0.001)	34.3 vs. 17.9% (NS)	36.5 vs. 19.5% (NS)	21.0 vs. 19.5% (NS)
Preadmission ALT, U/L Abnormal (%)	23.2 vs. 11.8% (<0.001)	38.0 vs. 8.9% (<0.001)	25.9 vs. 18.4% (NS)	23.8 vs. 19.3% (NS)	18.1 vs. 20.6% (NS)
Preadmission ALP, U/L Abnormal (%)	13.4 vs. 13.1% (NS)	13.8 vs. 13.1% (NS)	56.8 vs. 6.6% (<0.001)	20.6 vs. 13.0% (<0.001)	9.9 vs. 15.9% (0.006)
Preadmission TBIL, mg/dL Abnormal (%)	5.0 vs. 2.9% (NS)	3.4 vs. 4.6% (NS)	7.0 vs. 3.7% (0.015)	44.4 vs. 2.1 (<0.001)	5.1 vs 3.1% (NS)

AST = aspartate aminotransferase; ALT = alanine aminotransferase; ALP = alkaline phosphatase; TBIL = total bilirubin; NS = not significant; BMI = body mass index